I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Share this page: More
Gregory V. Carr
Primary Department Affiliation: Pharmacology and Molecular Sciences; Lieber Institute for Brain Development
Degree: Ph.D., University of Pennsylvania
Rank: Assistant Professor
School of Medicine Address: Room 373, John G. Rangos, Sr., Building, 855 N. Wolfe Street, Baltimore, MD 21205
Preclinical models of neurological and psychiatric disorders.
Psychiatric disorders and related neurodevelopmental disorders result from the complex interaction of multiple genetic and environmental risk factors. Our laboratory uses rodent models to determine how these risk factors modulate neurobiology and behavior. We utilize neurochemical, electrophysiological, and behavioral assays to interrogate the neural systems thought to be impaired in neurodevelopmental disorders. Our ultimate goal is to use this knowledge to inform drug discovery efforts designed to increase and improve the treatment options available for central nervous system disorders. We also conduct research focused on developing novel behavioral assays with increased translational value for screening novel therapeutics.
Carr, G.V., Bangasser, D.A., Bethea, T., Young, M., Valentino, R.J., Lucki, I. Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats. Neuropsychopharmacology 2010; 35 (3): 752-763. Pub Med Reference
Carr, G.V., Lucki, I. The role of serotonin receptor subtypes in treating depression: A review of animal studies. Psychopharmacology 2011; 213 (2-3): 265-287. Pub Med Reference
Carr, G.V., Schechter, L.E., Lucki, I. Antidepressant and anxiolytic effects of selective 5-HT6 receptor agonists. Psychopharmacology 2011; 213 (2-3): 499-507. Pub Med Reference
Carr, G.V.*, Jenkins, K.A.*, Weinberger, D.R., Papaleo, F. Loss of dysbindin‐1 in mice impairs reward‐based operant learning by increasing impulsive and compulsive behavior. Behavioural Brain Research 2013; 241: 173-184. *These authors contributed equally to this work. Pub Med Reference
Papaleo, F., Yang, F., Paterson, C., Palumbo, S., Carr, G.V., Wang, Y., Floyd, K., Huang, W., Thomas, C.J., Chen, J., Weinberger, D.R., Law, A.J. Behavioral, Neurophysiological, and Synaptic Impairment in a Transgenic Neuregulin1 (NRG1-IV) Murine Schizophrenia Model. J Neurosci. 2016 Apr 27;36(17):4859-75. Pub Med References
Detrait, E.R., Carr, G.V., Weinberger, D.R., Lamberty, Y. Brain catechol-O-methyltransferase (COMT) inhibition by tolcapone counteracts recognition memory deficits in normal and chronic phencyclidine-treated rats and in COMT-Val transgenic mice. Behav Pharmacol. 2016 Aug;27(5):415-21. Pub Med References
Carr, G.V., Chen, J., Yang, F., Ren, M., Yuan, P., Tian, Q., Bebensee, A., Zhang, G.Y., Du, J., Glineburg, P., Xun, R., Akhile, O., Akuma, D., Pickel, J., Barrow, J.C., Papaleo, F., Weinberger, D.R. KCNH2-3.1 expression impairs cognition and alters neuronal function in a model of molecular pathology associated with schizophrenia. Molecular Psychiatry 2016 [Epub ahead of print]. Pub Med References
Other graduate program in which Dr. Carr participates: